Comparative Pharmacology
Head-to-head clinical analysis: PRINIVIL versus VASOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRINIVIL versus VASOTEC.
PRINIVIL vs VASOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an angiotensin-converting enzyme inhibitor that decreases angiotensin II production, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Enalaprilat, the active metabolite of enalapril, competitively inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and afterload.
Initial dose 10 mg orally once daily; titrate to target dose of 20-40 mg daily based on blood pressure response.
2.5 to 10 mg orally twice daily; initial dose 5 mg once daily; titrate based on blood pressure response; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours, with accumulation noted in renal impairment; effective half-life at steady state extends to 30-50 hours in patients with creatinine clearance <30 mL/min.
Terminal half-life of enalaprilat is 35-38 hours, with multiple-dose half-life ~11 hours due to prolonged terminal phase; clinical context: once-daily dosing achieves steady-state in 3-4 days.
Renal excretion accounts for approximately 60% of total clearance, primarily as unchanged lisinopril; fecal excretion accounts for negligible amounts.
Renal: 60-70% as enalaprilat; fecal: 20-30% as enalaprilat; biliary: minor (<10%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor